Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1181 to 1190 of 1864 total matches.

A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018  (Issue 1539)
schedule, with doses given on day 0, day 7, and day 21-30, and a booster dose given at month 12. HB ...
The FDA has approved a two-dose hepatitis B virus (HBV) vaccine (Heplisav-B – Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses. Engerix-B and Recombivax HB are licensed for use in persons of all ages. A combination hepatitis A/B vaccine (Twinrix) contains the same hepatitis B component as Engerix-B and is licensed for use only in adults.
Med Lett Drugs Ther. 2018 Jan 29;60(1539):17-8 |  Show IntroductionHide Introduction

Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
hour before to 8 hours after taking the drug. The cost of 30 days’ treatment with either strength ...
The FDA has approved a sublingual tablet (Nocdurna – Ferring) and a nasal spray (Noctiva – Avadel) formulation of desmopressin acetate for treatment of nocturia due to nocturnal polyuria in adults who wake up ≥2 times per night to void. Nocdurna and Noctiva are the first two products to be approved in the US for this indication. Higher-strength nasal spray and oral tablet formulations of desmopressin (DDAVP, and others) have been available for years for treatment of diabetes insipidus and primary nocturnal enuresis (bedwetting in children). In 2007, the indication for primary...
Med Lett Drugs Ther. 2019 Mar 25;61(1568):46-8 |  Show IntroductionHide Introduction

Rimegepant (Nurtec ODT) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
). The safety of treating >15 migraine attacks in a 30-day period with rimegepant has not been established ...
The FDA has approved an orally disintegrating tablet (ODT) formulation of rimegepant (Nurtec ODT – Biohaven), a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), for acute treatment of migraine with or without aura in adults. Rimegepant is the second oral gepant to become available in the US; ubrogepant (Ubrelvy), which is approved for the same indication, was the first. Four parenteral CGRP antagonists, erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti), are approved for prevention of...
Med Lett Drugs Ther. 2020 May 4;62(1597):70-2 |  Show IntroductionHide Introduction

MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
) to ≥1:16 (day 30; ≥1:8 in Chang et al), or a ≥4-fold increase at day 30 from a baseline of ≥1:8 ...
The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y (MenACWY) in persons ≥2 years old.
Med Lett Drugs Ther. 2021 May 17;63(1624):78-80 |  Show IntroductionHide Introduction

Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
days. They were evaluated at 8 time points over a 13-hour period using the SKAMP rating scale, a 13 ...
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate (Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):157-9 |  Show IntroductionHide Introduction

Tramadol/Celecoxib (Seglentis) for Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022  (Issue 1648)
in additive effects. Use of a monoamine oxidase (MAO) inhibitor with or within 14 days of tramadol ...
The FDA has approved Seglentis (Esteve/Kowa), an oral combination of tramadol hydrochloride, a weak opioid agonist and weak serotonin and norepinephrine reuptake inhibitor (SNRI), and celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID), for use in adults with acute pain that is severe enough to require an opioid and for which alternative treatment options are inadequate.
Med Lett Drugs Ther. 2022 Apr 18;64(1648):58-60 |  Show IntroductionHide Introduction

Rosiglitazone/Glimepiride (Avandaryl) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
mg once 29.10 Amaryl (Aventis) (max 8 mg) 38.70 1. Cost of 30 days’ treatment (8 mg/d ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
Med Lett Drugs Ther. 2006 Mar 13;48(1230):22-4 |  Show IntroductionHide Introduction

Telavancin (Vibativ) for Gram-Positive Skin Infections

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010  (Issue 1329)
4.50 Bactrim DS (Mutual) 7.41 1. Cost of 1 day’s treatment of a 70 kg patient according to AWP ...
Telavancin (Vibativ - Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria in adults.
Med Lett Drugs Ther. 2010 Jan 11;52(1329):1-2 |  Show IntroductionHide Introduction

Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025  (Issue 1724)
mg/60 mg/150 mg once/day in patients ...
The FDA has approved Alyftrek (Vertex), an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily treatment of cystic fibrosis (CF) in patients ≥6 years old who have at least one F508del mutation or another responsive mutation in the CFTR gene. This is the first approval for vanzacaftor and for deutivacaftor, a deuterated form of ivacaftor. Trikafta, a twice-daily oral fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor, is FDA-approved for the same indication...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):41-3   doi:10.58347/tml.2025.1724a |  Show IntroductionHide Introduction

In Brief: Lowering the Dose of Lunesta

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014  (Issue 1444)
occur. 1. FDA Drug Safety Communication. FDA warns of next-day impairment with sleep aid Lunesta ...
The FDA has required the manufacturer of eszopiclone (Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours.1 Eszopiclone’s half-life is longer than that of any other drug in its class, which includes zolpidem (Ambien, and generics) and zaleplon (Sonata, and generics).All benzodiazepine receptor agonists may impair performance the next morning,...
Med Lett Drugs Ther. 2014 Jun 9;56(1444):48 |  Show IntroductionHide Introduction